<DOC>
	<DOCNO>NCT00499083</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel , cyclophosphamide , doxorubicin , work different way stop growth tumor cell , either kill cell stop dividing . Injecting patient 's dendritic cell directly tumor may stimulate immune system stop tumor cell grow . Radiation therapy use high-energy x-ray kill tumor cell . Estrogen cause growth breast cancer cell . Hormone therapy use tamoxifen may fight breast cancer block use estrogen tumor cell . Giving combination chemotherapy together autologous dendritic cell surgery may make tumor small reduce amount normal tissue need remove . Giving radiation therapy hormone therapy surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study side effect well give paclitaxel together cyclophosphamide doxorubicin follow autologous dendritic cell surgery without radiation therapy and/or hormone therapy work treat woman stage II stage III breast cancer .</brief_summary>
	<brief_title>Paclitaxel , Cyclophosphamide , Doxorubicin Followed Autologous Dendritic Cells Surgery With Without Radiation Therapy and/or Hormone Therapy Treating Women With Stage II Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Assess safety intratumoral ( IT ) autologous dendritic cell ( DC ) injection woman stage II III breast cancer receive neoadjuvant paclitaxel , cyclophosphamide , doxorubicin hydrochloride follow surgery without adjuvant radiotherapy and/or hormone therapy . - Determine clinical pathologic response patient treat regimen . - Determine immune response , term tumor cell apoptosis presence characterization tumor infiltrate white blood cell resect breast cancer , patient treat regimen . - Determine IT DC injection administer neoadjuvant chemotherapy-induced tumor cell apoptosis induce T-cell response tumor antigens patient . OUTLINE : This open-label study . - Leukapheresis : Patients undergo leukapheresis baseline collect peripheral blood mononuclear cell dendritic cell ( DC ) culture . - Neoadjuvant , dose-dense chemotherapy : Patients receive paclitaxel IV least 3 hour day 1 filgrastim ( G-CSF ) subcutaneously ( SC ) day 4-14 pegfilgrastim SC day 2 . Treatment repeat every 2 week 4 course absence disease progression unacceptable toxicity . Beginning 2 week completion paclitaxel chemotherapy , patient receive cyclophosphamide IV doxorubicin hydrochloride IV day 1 G-CSF SC day 4-14 pegfilgrastim SC day 2 . Treatment repeat every 2 week 4 course absence disease progression unacceptable toxicity . - Intratumoral injection autologous DCs : Intratumoral autologous DCs inject primary breast mass palpable axillary node day 7 1st , 2nd , 3rd course paclitaxel chemotherapy . If tumor localize ultrasound course chemotherapy , DCs inject site tumor bed previously localize clip marker . In event previously inject primary tumor localize ultrasound , palpable lymph node , still present , injected rather tissue next primary tumor clip marker . - Definitive breast surgery : Within 2-4 week completion neoadjuvant chemotherapy , patient undergo modified radical mastectomy lumpectomy without standard axillary node dissection . * NOTE : *Standard axillary node dissection require node assessment do prior chemotherapy pre-chemotherapy sentinel node positive . - Radiotherapy : Patients undergo lumpectomy residual disease require chest wall radiotherapy mastectomy ( e.g. , T3 T4 breast lesion 4 axillary lymph node ) undergo radiotherapy 2-4 week surgery . - Hormone therapy : Patients estrogen and/or progesterone receptor-positive tumor receive adjuvant hormone therapy ≥ 5 year . Premenopausal patient receive tamoxifen citrate post- perimenopausal patient receive either tamoxifen citrate aromatase inhibitor ( AI ) , drug sequence , determine treat oncologist . Peripheral blood sample obtain DC injection , staging/biopsy , periodically 2 year . Blood sample analyze ELISPOT ELISA assay evaluation immune response . Tumor tissue obtain core biopsy breast primary and/or palpable axillary lymph node baseline completion paclitaxel chemotherapy . Tumor tissue analyze IHC RT-PCR COX-2 VEGF-A -C expression level , well T-cell DC infiltration tumor . T-cell DC infiltration evaluate correlation clinical outcome diagnosis , midpoint biopsy follow paclitaxel chemotherapy , definitive surgery . After completion study therapy , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast cancer meeting follow criterion : Primary tumor ≥ 3 cm mammography , ultrasound , palpation AND/OR palpable axillary lymph node &gt; 1 cm Survivin and/or carcinoembryonic antigenpositive IHC Tumor must localize exam ultrasound allow tumor injection No stage IV metastatic disease HER2/neunegative tumor IHC If 2+ indeterminate range , test HER2/neu overexpression fluorescent situ hybridization ( FISH ) require Hormone receptor status know PATIENT CHARACTERISTICS : Female Pre , peri , postmenopausal ECOG performance status 01 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month follow completion study therapy ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Alkaline phosphatase ≤ 1.5 time upper limit normal ( ULN ) Total bilirubin ≤ 1.5 time ULN AST ALT ≤ 1.5 time ULN Creatinine &lt; 1.5 time ULN No active serious infection No prior malignancy except adequately treat basal cell squamous cell skin cancer , noninvasive carcinoma , cancer patient disease free 5 year No comorbidity condition would interfere study assessment procedure preclude study participation PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>